This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.

Non-invasive cardiac diagnostics

We have developed an innovative technology which is going to revolutionize the cardiovascular disease diagnostic approach and help to avoid unnecessary invasive procedures.

Quick, safe and accurate diagnostic tool for assessing coronary artery disease severity

Detailed anatomical and functional evaluation of coronary arteries

Our technologies

Cardiolens FFR-CT Pro®

The FFR-CT-based technology developed by HEMOLENS allows for a detailed anatomical and functional evaluation of coronary arteries.

Diagnostic methods currently under development

The foundation of our testing methods is our innovative technology based on computational fluid mechanics.


Michał Sobański, MD

Department of General, Operational and Neuroradiology Radiology, University Clinical Hospital in Wroclaw, Poland

I truly believe that together with Hemolens Diagnostics we will develop a new standard that will allow us to apply the non-invasive FFR-CT diagnostic tool in patients with intermediate-risk coronary artery disease. These are patients who, considering the contraindications, would not be eligible for invasive diagnostic work-up.

Cezary Kępka, MD, PhD

National Institute of Cardiology in Anin, Poland

With FFR-CT, Hemolens Diagnostics offers a promising new technology to detect anatomically and functionally significant coronary artery stenosis on the basis of non-invasive examinations: coronary computed tomography angiography (CCTA) and continuous non-invasive blood pressure (CNBP) monitoring. The solution has already been CE-certified, which will allow it to pave its way into clinical practice. Methods based on measuring fractional flow reserve (FFR) from computed tomography scans of coronary arteries are recommended by international scientific associations.

Adrian Korbecki, MD

Department of General, Operational and Neuroradiology Radiology, University Clinical Hospital in Wroclaw, Poland

I became involved in the Hemolens Diagnostics project because I believe that advancements in technology can redefine the limits of existing testing procedures and provide clinical practitioners with ever more detailed insights. Non-invasive methods are the future of medicine.


This is a medical device. Use it in accordance with the instructions.

Intended Use:

Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement. The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.